Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Celldex Therapeutics, Inc. (CLDX : NSDQ)

• Company Description    CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates. Number of Employees: 186

• Price / Volume Information    Yesterday's Closing Price: $24.45 Daily Weekly Monthly 20 Day Moving Average: 1,581,133 shares Shares Outstanding: 66.41 (millions) Market Capitalization: $1,623.65 (millions) Beta: 1.19 52 Week High: $47.00 52 Week Low: $14.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.96% -3.69% 12 Week 17.43% 6.67% Year To Date -3.24% -10.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 53 FRONTAGE ROAD SUITE 220 - HAMPTON,NJ 08827 USA ph: 908-200-7500 fax: 908-454-1911 ir@celldex.com http://www.celldex.com

• General Corporate Information    Officers Anthony S. Marucci - President; Chief Executive Officer and Director Karen L. Shoos - Chairman and Director Sam Martin - Senior Vice President; Chief Financial Officer and Keith L. Brownlie - Director Cheryl L. Cohen - Director Peer Information Celldex Therapeutics, Inc. (CORR.) Celldex Therapeutics, Inc. (RSPI) Celldex Therapeutics, Inc. (CGXP) Celldex Therapeutics, Inc. (BGEN) Celldex Therapeutics, Inc. (GTBP) Celldex Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 15117B202 SIC: 2835 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 66.41 Most Recent Split Date: 2.00 (0.07:1) Beta: 1.19 Market Capitalization: $1,623.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.42 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.48 Price/Cash Flow: - Price / Sales: 280.37 EPS Growth vs. Year Ago Period: -57.41% vs. Previous Quarter: -4.94% Sales Growth vs. Year Ago Period: -70.78% vs. Previous Quarter: 5.04% ROE 06/30/25 - -27.61 03/31/25 - -23.46 12/31/24 - -19.83 ROA 06/30/25 - -26.20 03/31/25 - -22.35 12/31/24 - -18.96 Current Ratio 06/30/25 - 19.67 03/31/25 - 21.67 12/31/24 - 18.92 Quick Ratio 06/30/25 - 19.67 03/31/25 - 21.67 12/31/24 - 18.91 Operating Margin 06/30/25 - -3,446.88 03/31/25 - -2,366.07 12/31/24 - -2,248.76 Net Margin 06/30/25 - -3,446.88 03/31/25 - -2,366.07 12/31/24 - -2,248.76 Pre-Tax Margin 06/30/25 - -3,446.88 03/31/25 - -2,366.07 12/31/24 - -2,248.76 Book Value 06/30/25 - 9.87 03/31/25 - 10.59 12/31/24 - 11.26 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©